BrioHealth Solutions, a US-based company developing the BrioVAD System, a Left Ventricular Assist Device (LVAD), announced on Monday that the 100th participant has been enrolled in the system's INNOVATE Trial.
Launched in late 2024, the INNOVATE Trial is a national research study to evaluate an innovative mechanical heart pump designed to help patients whose hearts can no longer pump enough blood on their own. The trial aims to evaluate the BrioVAD System to develop more reliable and longer-lasting devices that can improve both survival and quality of life.
The BrioVAD System is designed to augment blood flow, enhance patient comfort, and minimise complications, while prioritising patient well-being and reduce the occurrence of adverse events associated with advanced heart failure treatment.
Philips launches InkSpace Imaging Snuggle coil for 3.0T MRI systems
Realheart secures European patent for artificial heart technology
Median Technologies secures FDA clearance for AI lung cancer screening software
Eli Lilly to invest over USD3.5bn in new Pennsylvania plant
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval
Apiject to open new generic injectable drug manufacturing facility in Apex, NC
Zylox-Tonbridge agrees staged acquisition of Germany's Optimed
Kestra partners with Biobeat to add cuffless blood pressure monitoring to wearable defibrillator
Boston Scientific to acquire Valencia Technologies to expand overactive bladder portfolio
EQT Life Sciences exits Vivasure Medical in EUR185m sale to Haemonetics